Skip to main content
Log in

Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration

Evidence for tissue aglycone formation

  • Original Articles
  • Anthracycline Distribution
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent with the known hepatobiliary excretion of AD 32 and metabolites. Significant accumulations of radioactivity and fluorescence were found in kidney, spleen, large intestine (including contents), lung, and heart. Lesser levels were found in muscle and fat. Little radioactivity and fluorescence were found in brain. Liquid chromatographic analysis of extracts of small intestine and liver homogenates showed N-trifluoroacetyladriamycin (AD 41) as the major fluorescent species, and also revealed N-trifluoroacetyladriamycinol (AD 92) and occasional low levels of AD 32. In addition, there was a major peak of nonfluorescent radioactive material and two fluorescent nonradioactive signals (unknowns 1 and 2), indicative of cleavage of the radiolabel from the chromophore.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

AD 32:

N-trifluoroacetyladriamycin-14-valerate

AD 41:

N-trifluoroacetyladriamycin

AD 92:

N-trifluoroacetyladriamycinol

ADR:

adriamycin

AD 48:

adriamycin-14-valerate

AD 60:

13-dihydro-N-trifluoroacetyladriamycin-14-valerate

AMNOL:

adriamycinol

HPLC:

high-performance liquid chromatography

TLC:

thin layer chromatography

SDS:

sodium dodecylsulfate

References

  1. Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E III (1979) An initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD 32), an adriamycin analog. Cancer Treat Rep 63: 919

    Google Scholar 

  2. Garnick MB, Israel M, Pegg WJ, Blum RH, Smith E, Frei E III (1979) Hepatobiliary pharmacokinetics of AD 32 in man. Proc Am Assoc Cancer Res/ASCO 20: 206

    Google Scholar 

  3. Henderson IC, Billingham M, Israel M, Krishan A, Frei E III (1978) Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits. Proc Am Assoc Cancer Res/ASCO 19: 158

    Google Scholar 

  4. Israel M, Modest EJ (1977) N-Trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same. U.S. Patent No. 4,035,566, July 12

  5. Israel M, Modest EJ, Frei E III (1975) N-Trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35: 1365

    Google Scholar 

  6. Israel M, Pegg WJ, Seshadri R, Parker LM (1976) N-Trifluoroacetyladriamycin-14-valerate (AD 32): Some in vivo structure-activity relationships. Abstracts, Fifth International Symposium on Medicinal Chemistry, Paris, France, July, p 63

  7. Israel M, Pegg WJ, Wilkinson PM (1978a) Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate. J Pharmacol Exp Ther 204: 696

    Google Scholar 

  8. Israel M, Wilkinson PM, Pegg WJ, Frei E III (1978b) Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat. Cancer Res 38: 365

    Google Scholar 

  9. Israel M, Karkowsky AM, Pegg WJ (1980a) Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32): Comparison of total anthracycline fluorescence and ratioactivity in mouse serum and urine. Cancer Chemother Pharmacol 4: 79

    Google Scholar 

  10. Israel M, Wilkinson PM, Osteen RT (1980b) Pharmacology studies with adriamycin and N-trifluoroacetyladriamycin-14-valerate (AD 32) in cynomolgus monkeys: Additional evidence for the abscence of an adriamycin-prodrug mechanism for AD 32. In: Crooke ST, Reich SD (eds) Anthracyclines: Current status and new developments. Academic Press, New York, pp 431–444

    Google Scholar 

  11. Israel M, Garnick MB, Pegg WJ, Blum RH, Frei E III (1978) Preliminary pharmacology of AD 32 in man. Proc Am Assoc Cancer Res/ASCO 19: 160

    Google Scholar 

  12. Parker LM, Hirst M, Israel M (1978) N-Trifluoroacetyladriamycin-14-valerate: Additional mouse antitumor and toxicity studies. Cancer Treat Rep 62: 119

    Google Scholar 

  13. Vecchi A, Cairo M, Mantovani A, Sironi M, Spreafico F (1978) Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Treat Rep 62: 111

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Israel, M., Karkowsky, A.M. & Khetarpal, V.K. Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Cancer Chemother. Pharmacol. 6, 25–30 (1981). https://doi.org/10.1007/BF00253006

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00253006

Keywords

Navigation